Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission

AIMS: Genetic and pharmacological inhibition of mitochondrial fission induced by acute myocardial ischaemia/reperfusion injury (IRI) has been shown to reduce myocardial infarct size. The clinically used anti-hypertensive and heart failure medication, hydralazine, is known to have anti-oxidant and an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalkhoran, Siavash Beikoghli, Kriston-Vizi, Janos, Hernandez-Resendiz, Sauri, Crespo-Avilan, Gustavo E, Rosdah, Ayeshah A, Lees, Jarmon G, Costa, Joana Rodrigues Simoes Da, Ling, Naomi X Y, Holien, Jessica K, Samangouei, Parisa, Chinda, Kroekkiat, Yap, En Ping, Riquelme, Jaime A, Ketteler, Robin, Yellon, Derek M, Lim, Shiang Y, Hausenloy, Derek J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752357/
https://www.ncbi.nlm.nih.gov/pubmed/33386841
http://dx.doi.org/10.1093/cvr/cvaa343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752357/
https://www.ncbi.nlm.nih.gov/pubmed/33386841
http://dx.doi.org/10.1093/cvr/cvaa343

Ejemplares similares